Anup Kumar Trikannad Ashwini Kumar
Assistant Professor
faculty
COM | Internal Med Hem-Onc
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Anup Kumar Trikannad Ashwini Kumar's research focuses on hematologic malignancies, particularly multiple myeloma and Hodgkin lymphoma. He has investigated the clinical outcomes and survival trends associated with extranodal Hodgkin lymphoma, utilizing population-based data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Additionally, his work includes analyzing the incidence, survival, and demographic patterns of B-cell prolymphocytic leukemia. Dr. Kumar has also explored therapeutic interventions, such as the use of Teclistamab in treating immune thrombocytopenia in patients with multiple myeloma. His research network includes collaborators from the University of Arkansas at Fayetteville and the University of Arkansas for Medical Sciences.
Metrics
- h-index: 2
- Publications: 11
- Citations: 8
Selected Publications
-
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)
-
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)
-
Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia (2024)
Collaboration Network
Top Collaborators
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Clinical outcomes in patients diagnosed with extra-nodal Hodgkin lymphoma: a 20-year retrospective analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database
- Demographic Analysis of Survival Trends in Extranodal Hodgkin Lymphoma: A Population-Based Study
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Clinical outcomes in patients diagnosed with extra-nodal Hodgkin lymphoma: a 20-year retrospective analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database
- Demographic Analysis of Survival Trends in Extranodal Hodgkin Lymphoma: A Population-Based Study
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Clinical outcomes in patients diagnosed with extra-nodal Hodgkin lymphoma: a 20-year retrospective analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database
- Demographic Analysis of Survival Trends in Extranodal Hodgkin Lymphoma: A Population-Based Study
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Clinical outcomes in patients diagnosed with extra-nodal Hodgkin lymphoma: a 20-year retrospective analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database
- Demographic Analysis of Survival Trends in Extranodal Hodgkin Lymphoma: A Population-Based Study
- Clinical outcomes in patients diagnosed with extra-nodal Hodgkin lymphoma: a 20-year retrospective analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database
- Demographic Analysis of Survival Trends in Extranodal Hodgkin Lymphoma: A Population-Based Study
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Similar Researchers
Based on overlapping research topics